AKT in cancer: new molecular insights and advances in drug development

Area of Science:

• Oncology
• Molecular Biology
• Biochemistry

Background:

• The phosphatidylinositol-3 kinase (PI3K)-AKT pathway is a critical regulator of cell survival, growth, and metabolism.
• This pathway is frequently dysregulated in various human cancers through genetic mutations, copy number alterations, and epigenetic changes.
• Dysregulation of the PI3K-AKT pathway disrupts the balance between cell proliferation and programmed cell death, contributing to tumorigenesis.

Purpose of the Study:

• To review the key features of the PI3K-AKT pathway.
• To summarize the evidence linking PI3K-AKT pathway dysregulation to cancer development.
• To discuss recent advancements in developing therapeutic agents targeting AKT for cancer treatment.

Main Methods:

• Literature review of the PI3K-AKT pathway.
• Analysis of evidence for the pathway's role in tumorigenesis.
• Survey of current therapeutic strategies targeting AKT.

Main Results:

• The PI3K-AKT pathway is a central regulator of cell homeostasis.
• Aberrant PI3K-AKT signaling is a hallmark of many cancers.
• AKT's downstream effectors are crucial for cancer cell survival and proliferation.
• Targeting AKT presents a promising therapeutic avenue.

Conclusions:

• The PI3K-AKT pathway is a significant driver of cancer.
• AKT is an attractive, albeit challenging, therapeutic target.
• Ongoing research focuses on developing effective AKT-targeting agents for cancer therapy.